{"entity":{"type":"insider","cik":"0001817217","url":"/insider/0001817217","json_url":"/insider/0001817217.json","name":"van Houte Hans","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":45,"n_filings":35,"first":"2021-02-22","last":"2026-08-04","span_basis":"filed_date"},"name_variants":[{"name":"van Houte Hans","source":"filing","n_filings":35,"first_seen":"2021-02-22","last_seen":"2026-08-04"}],"transactions":[{"id":6047165,"accession":"0001817217-26-000012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001817217-26-000012","line_url":"/filing/0001817217-26-000012","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4761.0,"shares_display":"4,761","price_per_share":24.362417391304348,"price_display":"24.36","price_state":"stated","total_value":115989.4692,"total_display":"115,989.47","total_whole":"115,989","shares_owned_after":40166.0,"shares_owned_after_display":"40,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-04","filed_date":"2026-08-04","scope":"insider","n_lines":2},{"id":5779362,"accession":"0001817217-26-000010","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001817217-26-000010","line_url":"/filing/0001817217-26-000010#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2845.0,"shares_display":"2,845","price_per_share":23.3828,"price_display":"23.38","price_state":"stated","total_value":66524.066,"total_display":"66,524.07","total_whole":"66,524","shares_owned_after":44927.0,"shares_owned_after_display":"44,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-07-30","scope":"insider"},{"id":6141635,"accession":"0001817217-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001817217-26-000008","line_url":"/filing/0001817217-26-000008","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14055.0,"shares_display":"14,055","price_per_share":16.600424546424758,"price_display":"16.60","price_state":"stated","total_value":233318.967,"total_display":"233,318.97","total_whole":"233,319","shares_owned_after":38174.0,"shares_owned_after_display":"38,174","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-05","scope":"insider","n_lines":2},{"id":5876645,"accession":"0001817217-26-000006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001817217-26-000006","line_url":"/filing/0001817217-26-000006#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2388.0,"shares_display":"2,388","price_per_share":16.6453,"price_display":"16.65","price_state":"stated","total_value":39748.9764,"total_display":"39,748.98","total_whole":"39,749","shares_owned_after":51647.0,"shares_owned_after_display":"51,647","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-30","filed_date":"2026-04-30","scope":"insider"},{"id":5911786,"accession":"0001817217-26-000002","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001817217-26-000002","line_url":"/filing/0001817217-26-000002","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3661.0,"shares_display":"3,661","price_per_share":16.59833458071565,"price_display":"16.60","price_state":"stated","total_value":60766.5029,"total_display":"60,766.50","total_whole":"60,767","shares_owned_after":45500.0,"shares_owned_after_display":"45,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-30","filed_date":"2026-01-30","scope":"insider","n_lines":2},{"id":4778376,"accession":"0001817217-25-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001817217-25-000005","line_url":"/filing/0001817217-25-000005#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6284.0,"shares_display":"6,284","price_per_share":12.5607,"price_display":"12.56","price_state":"stated","total_value":78931.4388,"total_display":"78,931.44","total_whole":"78,931","shares_owned_after":37592.0,"shares_owned_after_display":"37,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-03","scope":"insider"},{"id":4155403,"accession":"0001817217-25-000003","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001817217-25-000003","line_url":"/filing/0001817217-25-000003#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3130.0,"shares_display":"3,130","price_per_share":12.7967,"price_display":"12.80","price_state":"stated","total_value":40053.671,"total_display":"40,053.67","total_whole":"40,054","shares_owned_after":43876.0,"shares_owned_after_display":"43,876","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-30","filed_date":"2025-10-30","scope":"insider"},{"id":4081815,"accession":"0001549595-25-000103","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-25-000103","line_url":"/filing/0001549595-25-000103#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5402.0,"shares_display":"5,402","price_per_share":11.0325,"price_display":"11.03","price_state":"stated","total_value":59597.565,"total_display":"59,597.56","total_whole":"59,598","shares_owned_after":35512.0,"shares_owned_after_display":"35,512","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-01","filed_date":"2025-08-01","scope":"insider"},{"id":5013947,"accession":"0001549595-25-000101","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001549595-25-000101","line_url":"/filing/0001549595-25-000101#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4304.0,"shares_display":"4,304","price_per_share":12.011,"price_display":"12.01","price_state":"stated","total_value":51695.344,"total_display":"51,695.34","total_whole":"51,695","shares_owned_after":40914.0,"shares_owned_after_display":"40,914","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-30","filed_date":"2025-07-30","scope":"insider"},{"id":5013925,"accession":"0001549595-25-000063","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-25-000063","line_url":"/filing/0001549595-25-000063#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6198.0,"shares_display":"6,198","price_per_share":11.3331,"price_display":"11.33","price_state":"stated","total_value":70242.5538,"total_display":"70,242.55","total_whole":"70,243","shares_owned_after":33724.0,"shares_owned_after_display":"33,724","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-02","filed_date":"2025-05-02","scope":"insider"},{"id":4120981,"accession":"0001549595-25-000059","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-25-000059","line_url":"/filing/0001549595-25-000059#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2438.0,"shares_display":"2,438","price_per_share":11.5017,"price_display":"11.50","price_state":"stated","total_value":28041.1446,"total_display":"28,041.14","total_whole":"28,041","shares_owned_after":39922.0,"shares_owned_after_display":"39,922","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-30","filed_date":"2025-04-30","scope":"insider"},{"id":4966663,"accession":"0001549595-25-000037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001549595-25-000037","line_url":"/filing/0001549595-25-000037","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5825.0,"shares_display":"5,825","price_per_share":14.487161373390558,"price_display":"14.49","price_state":"stated","total_value":84387.715,"total_display":"84,387.72","total_whole":"84,388","shares_owned_after":34424.0,"shares_owned_after_display":"34,424","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-03","scope":"insider","n_lines":2},{"id":4894022,"accession":"0001549595-25-000020","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001549595-25-000020","line_url":"/filing/0001549595-25-000020","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2811.0,"shares_display":"2,811","price_per_share":19.853678406261118,"price_display":"19.85","price_state":"stated","total_value":55808.69,"total_display":"55,808.69","total_whole":"55,809","shares_owned_after":39803.0,"shares_owned_after_display":"39,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-30","filed_date":"2025-01-30","scope":"insider","n_lines":2},{"id":2252713,"accession":"0001549595-24-000153","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-24-000153","line_url":"/filing/0001549595-24-000153#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3546.0,"shares_display":"3,546","price_per_share":24.2762,"price_display":"24.28","price_state":"stated","total_value":86083.4052,"total_display":"86,083.41","total_whole":"86,083","shares_owned_after":33724.0,"shares_owned_after_display":"33,724","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-01","filed_date":"2024-11-01","scope":"insider"},{"id":2631862,"accession":"0001549595-24-000148","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-24-000148","line_url":"/filing/0001549595-24-000148#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2368.0,"shares_display":"2,368","price_per_share":24.305,"price_display":"24.30","price_state":"stated","total_value":57554.24,"total_display":"57,554.24","total_whole":"57,554","shares_owned_after":37270.0,"shares_owned_after_display":"37,270","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-30","filed_date":"2024-10-30","scope":"insider"},{"id":3206609,"accession":"0001549595-24-000112","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-24-000112","line_url":"/filing/0001549595-24-000112#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":25.2185,"price_display":"25.22","price_state":"stated","total_value":504370.0,"total_display":"504,370.00","total_whole":"504,370","shares_owned_after":31002.0,"shares_owned_after_display":"31,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-26","filed_date":"2024-08-26","scope":"insider"},{"id":2608656,"accession":"0001549595-24-000110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001549595-24-000110","line_url":"/filing/0001549595-24-000110","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3477.0,"shares_display":"3,477","price_per_share":21.44835015818234,"price_display":"21.45","price_state":"stated","total_value":74575.9135,"total_display":"74,575.91","total_whole":"74,576","shares_owned_after":51102.0,"shares_owned_after_display":"51,102","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-01","filed_date":"2024-08-01","scope":"insider","n_lines":2},{"id":2631844,"accession":"0001549595-24-000104","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-24-000104","line_url":"/filing/0001549595-24-000104#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2490.0,"shares_display":"2,490","price_per_share":20.6677,"price_display":"20.67","price_state":"stated","total_value":51462.573,"total_display":"51,462.57","total_whole":"51,463","shares_owned_after":54479.0,"shares_owned_after_display":"54,479","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-07-30","scope":"insider"},{"id":2401502,"accession":"0001549595-24-000088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-24-000088","line_url":"/filing/0001549595-24-000088#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":20.0108,"price_display":"20.01","price_state":"stated","total_value":400216.0,"total_display":"400,216.00","total_whole":"400,216","shares_owned_after":48333.0,"shares_owned_after_display":"48,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-20","filed_date":"2024-06-20","scope":"insider"},{"id":2401492,"accession":"0001549595-24-000057","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-24-000057","line_url":"/filing/0001549595-24-000057#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3499.0,"shares_display":"3,499","price_per_share":12.826,"price_display":"12.83","price_state":"stated","total_value":44878.174,"total_display":"44,878.17","total_whole":"44,878","shares_owned_after":68333.0,"shares_owned_after_display":"68,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-02","filed_date":"2024-05-02","scope":"insider"},{"id":2480574,"accession":"0001549595-24-000055","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-24-000055","line_url":"/filing/0001549595-24-000055#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1387.0,"shares_display":"1,387","price_per_share":12.0422,"price_display":"12.04","price_state":"stated","total_value":16702.5314,"total_display":"16,702.53","total_whole":"16,703","shares_owned_after":71832.0,"shares_owned_after_display":"71,832","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-30","filed_date":"2024-04-30","scope":"insider"},{"id":2426486,"accession":"0001549595-24-000034","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-24-000034","line_url":"/filing/0001549595-24-000034#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6812.0,"shares_display":"6,812","price_per_share":10.0151,"price_display":"10.02","price_state":"stated","total_value":68222.8612,"total_display":"68,222.86","total_whole":"68,223","shares_owned_after":68333.0,"shares_owned_after_display":"68,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-16","filed_date":"2024-02-16","scope":"insider"},{"id":2631825,"accession":"0001549595-24-000009","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-24-000009","line_url":"/filing/0001549595-24-000009#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1671.0,"shares_display":"1,671","price_per_share":7.9902,"price_display":"7.99","price_state":"stated","total_value":13351.6242,"total_display":"13,351.62","total_whole":"13,352","shares_owned_after":75145.0,"shares_owned_after_display":"75,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-01-30","scope":"insider"},{"id":7904160,"accession":"0001549595-23-000066","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-23-000066","line_url":"/filing/0001549595-23-000066#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3541.0,"shares_display":"3,541","price_per_share":10.0031,"price_display":"10.00","price_state":"stated","total_value":35420.9771,"total_display":"35,420.98","total_whole":"35,421","shares_owned_after":71930.0,"shares_owned_after_display":"71,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-20","filed_date":"2023-12-21","scope":"insider"},{"id":8083271,"accession":"0001549595-23-000064","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001549595-23-000064","line_url":"/filing/0001549595-23-000064#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10906.0,"shares_display":"10,906","price_per_share":10.003,"price_display":"10.00","price_state":"stated","total_value":109092.718,"total_display":"109,092.72","total_whole":"109,093","shares_owned_after":75471.0,"shares_owned_after_display":"75,471","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-19","filed_date":"2023-12-20","scope":"insider"},{"id":7932941,"accession":"0001549595-23-000060","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-23-000060","line_url":"/filing/0001549595-23-000060#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1080.0,"shares_display":"1,080","price_per_share":5.1974,"price_display":"5.20","price_state":"stated","total_value":5613.192,"total_display":"5,613.19","total_whole":"5,613","shares_owned_after":86377.0,"shares_owned_after_display":"86,377","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-31","filed_date":"2023-11-01","scope":"insider"},{"id":8155029,"accession":"0001209191-23-043982","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-043982","line_url":"/filing/0001209191-23-043982#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1245.0,"shares_display":"1,245","price_per_share":9.6547,"price_display":"9.65","price_state":"stated","total_value":12020.1015,"total_display":"12,020.10","total_whole":"12,020","shares_owned_after":82571.0,"shares_owned_after_display":"82,571","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-31","filed_date":"2023-08-01","scope":"insider"},{"id":8183204,"accession":"0001209191-23-026522","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-026522","line_url":"/filing/0001209191-23-026522#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":721.0,"shares_display":"721","price_per_share":9.8763,"price_display":"9.88","price_state":"stated","total_value":7120.8123,"total_display":"7,120.81","total_whole":"7,121","shares_owned_after":78930.0,"shares_owned_after_display":"78,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-01","filed_date":"2023-05-02","scope":"insider"},{"id":7967005,"accession":"0001209191-23-005908","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-005908","line_url":"/filing/0001209191-23-005908#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":924.0,"shares_display":"924","price_per_share":11.7796,"price_display":"11.78","price_state":"stated","total_value":10884.3504,"total_display":"10,884.35","total_whole":"10,884","shares_owned_after":76765.0,"shares_owned_after_display":"76,765","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-02-01","scope":"insider"},{"id":6107277,"accession":"0001209191-22-055146","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-055146","line_url":"/filing/0001209191-22-055146#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":739.0,"shares_display":"739","price_per_share":12.8805,"price_display":"12.88","price_state":"stated","total_value":9518.6895,"total_display":"9,518.69","total_whole":"9,519","shares_owned_after":74803.0,"shares_owned_after_display":"74,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-31","filed_date":"2022-11-01","scope":"insider"},{"id":6430733,"accession":"0001209191-22-043962","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-043962","line_url":"/filing/0001209191-22-043962#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":752.0,"shares_display":"752","price_per_share":15.67,"price_display":"15.67","price_state":"stated","total_value":11783.84,"total_display":"11,783.84","total_whole":"11,784","shares_owned_after":72656.0,"shares_owned_after_display":"72,656","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-01","filed_date":"2022-08-02","scope":"insider"},{"id":6390088,"accession":"0001209191-22-026890","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-026890","line_url":"/filing/0001209191-22-026890#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":697.0,"shares_display":"697","price_per_share":11.75,"price_display":"11.75","price_state":"stated","total_value":8189.75,"total_display":"8,189.75","total_whole":"8,190","shares_owned_after":2189.0,"shares_owned_after_display":"2,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-02","filed_date":"2022-05-03","scope":"insider"},{"id":5145878,"accession":"0001209191-21-014307","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-014307","line_url":"/filing/0001209191-21-014307#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35419.0,"shares_display":"35,419","price_per_share":39.9,"price_display":"39.90","price_state":"stated","total_value":1413218.1,"total_display":"1,413,218.10","total_whole":"1,413,218","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-24","filed_date":"2021-02-25","scope":"insider"},{"id":4773964,"accession":"0001209191-21-013353","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-013353","line_url":"/filing/0001209191-21-013353#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5330.0,"shares_display":"5,330","price_per_share":39.9323,"price_display":"39.93","price_state":"stated","total_value":212839.159,"total_display":"212,839.16","total_whole":"212,839","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-22","filed_date":"2021-02-23","scope":"insider"},{"id":5423030,"accession":"0001209191-21-012668","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-012668","line_url":"/filing/0001209191-21-012668","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817217","owner_name":"van Houte Hans","owner_display_name":"van Houte Hans","owner_url":"/insider/0001817217","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13583.0,"shares_display":"13,583","price_per_share":35.45763433703895,"price_display":"35.46","price_state":"stated","total_value":481621.0472,"total_display":"481,621.05","total_whole":"481,621","shares_owned_after":1066.0,"shares_owned_after_display":"1,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider","n_lines":5}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":45,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":45,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":45},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001549595","name":"Nurix Therapeutics, Inc.","url":"/issuer/0001549595","role":"Officer (Chief Financial Officer)","n_filings":35,"first_seen":"2021-02-22","last_seen":"2026-08-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001817217","retrieved_at":"2026-08-25T08:40:32+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}